Results 91 to 100 of about 1,927 (159)

Are new antiretroviral treatments increasing the risks of clinical obesity?

Journal of Virus Eradication, 2019
There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant.
Andrew Hill, Laura Waters, Anton Pozniak
doaj  

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

, 2007
John M. Murray, Sean Emery, Anthony D. Kelleher, Matthew Law, Joshua Chen, Daria J. Hazuda, Bach‐Yen Nguyen, Hedy Teppler, David A. Cooper   +8 more
openalex   +1 more source

Synthesis of Raltegravir [PDF]

Synfacts, 2017
openaire   +1 more source

Raltegravir for postexposure prophylaxis following occupational exposure to HIV

, 2008
Marc Siegel, Virginia L. Kan, Debra Benator   +2 more
openalex   +1 more source

Pharmacokinetics of the raltegravir/maraviroc/etravirine combination [PDF]

Journal of Antimicrobial Chemotherapy, 2011
CALCAGNO, Andrea, S. Nozza, BONORA, Stefano, A. Castagna, D. G. de, D'AVOLIO, ANTONIO, A. Lazzarin, DI PERRI, Giovanni   +7 more
openaire   +4 more sources

Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/Virtual

Journal of the International AIDS Society, Volume 27, Issue S6, November 2024.
wiley   +1 more source

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life [PDF]

, 2009
Philip Grant, Sarah Palmer, Eran Bendavid, Annie Talbot, Debbie Slamowitz, Pat Cain, S Kobayashi, Maya Balamane, Andrew Zolopa   +8 more
openalex   +1 more source

Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs

Качественная клиническая практика, 2018
Objective: To perform comprehensive pharmacoeconomical assessment of use etravirine and raltegravir in HIV-infected patients. Methodology: Cost-eifectiveness and budget impact analyses of etravirine or raltegravir on the top of optimized background ...
Y. I. Ashikhmin, D. Yu. Belousov
doaj  

Exacerbation of depression associated with starting raltegravir: a report of four cases

, 2008
Marianne Harris, Gerene Larsen, Julio Montaner   +2 more
openalex   +1 more source

Raltegravir‐induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: implications for clinical practice and patient safety [PDF]

, 2010
Meo Perry, Noor Almaani, Nemesha Desai, Julie Fox, N Larbalestier, Daniella Chilton   +5 more
openalex   +1 more source